Literature DB >> 19010354

A possible role of Fas-ligand-mediated "reverse signaling" in pathogenesis of rheumatoid arthritis and systemic lupus erythematosus.

Ekaterina Telegina1, Tatiana Reshetnyak, Anna Moshnikova, Olga Proussakova, Alexandra Zhukova, Alla Kuznetsova, Alexei Ivanov, Michail Paltsev, Igor Beletsky.   

Abstract

Fas/FasL system is involved in pathogenesis of a variety of autoimmune diseases. In overwhelming majority of situations alterations in Fas and FasL expression are viewed in frames of Fas-mediated apoptosis. In the present work we tested a possible involvement of Fas-ligand-mediated "reverse signaling" in pathogenesis of autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). We show that high level of sFas in RA patient blood correlates with a high activity of disease; in SLE patients with elevated sFas level there was a correlation between sFas concentration and leucopenia, and tissue and organ damage. We showed for the first time that at high concentrations in serum sFas is present in oligomeric form. Oligomeric sFas demonstrated cytotoxicity in lymphocyte primary culture and in transformed cells, while non-toxic recombinant Fas-ligand partially blocked this effect. Besides, immunohistochemical analysis of PBLs and injured synovia of RA patients revealed the high expression of Fas-ligand. All this together allow assuming the involvement of cytotoxic "reversed signaling" in the pathogenesis of autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19010354     DOI: 10.1016/j.imlet.2008.10.003

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  8 in total

Review 1.  Acute myeloid leukemia developing in patients with autoimmune diseases.

Authors:  Safaa M Ramadan; Tamer M Fouad; Valentina Summa; Syed Kh Hasan; Francesco Lo-Coco
Journal:  Haematologica       Date:  2011-12-16       Impact factor: 9.941

Review 2.  Targeting Fas in osteoresorptive disorders.

Authors:  Natasa Kovacic; Danka Grcevic; Vedran Katavic; Ivan Kresimir Lukic; Ana Marusic
Journal:  Expert Opin Ther Targets       Date:  2010-10       Impact factor: 6.902

3.  Association of Fas gene polymorphisms with systemic lupus erythematosus: a meta-analysis.

Authors:  Nan Xiang; Xiao-Mei Li; Guo-Sheng Wang; Jin-Hui Tao; Xiang-Pei Li
Journal:  Mol Biol Rep       Date:  2012-10-13       Impact factor: 2.316

Review 4.  The role of apoptosis proteins and complement components in the etiopathogenesis of systemic lupus erythematosus.

Authors:  Bernadete L Liphaus; Maria Helena Bittencourt Kiss
Journal:  Clinics (Sao Paulo)       Date:  2010-03       Impact factor: 2.365

5.  Increased Tim-3 expression on peripheral T lymphocyte subsets and association with higher disease activity in systemic lupus erythematosus.

Authors:  Li-jun Song; Xiao Wang; Xu-ping Wang; Dong Li; Feng Ding; Hua-xiang Liu; Xiao Yu; Xing-fu Li; Qiang Shu
Journal:  Diagn Pathol       Date:  2015-06-16       Impact factor: 2.644

6.  Impairment of Fas-ligand-caveolin-1 interaction inhibits Fas-ligand translocation to rafts and Fas-ligand-induced cell death.

Authors:  Xenia A Glukhova; Julia A Trizna; Olga V Proussakova; Vladimir Gogvadze; Igor P Beletsky
Journal:  Cell Death Dis       Date:  2018-01-22       Impact factor: 8.469

7.  Stronger Correlation between Interleukin 18 and Soluble Fas in Lupus Nephritis Compared with Mild Lupus.

Authors:  Mohammad Reza Hatef; Maryam Sahebari; Zahra Rezaieyazdi; Mohammad Reza Nakhjavani; Mahmoud Mahmoudi
Journal:  ISRN Rheumatol       Date:  2013-03-14

8.  Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus.

Authors:  Fabien B Vincent; Rangi Kandane-Rathnayake; Rachel Koelmeyer; James Harris; Alberta Y Hoi; Fabienne Mackay; Eric F Morand
Journal:  Lupus Sci Med       Date:  2020-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.